BP401T — Pharmaceutical Organic Chemistry III

✔ Correct — C: A stereocentre (chiral / asymmetric carbon) is sp³ and bonded to four different substituents → produces two non-superimposable mirror-image molecules (enantiomers). With n stereocentres, maximum 2ⁿ stereoisomers (lower if internal symmetry creates meso forms). Other types: chiral axes (allenes, biaryls), planes (helicenes), centres at S, P, N⁺. Glyceraldehyde — simplest chiral example: D and L forms.

✔ Correct — A: Enantiomers — pair of stereoisomers that are non-superimposable mirror images (like left and right hands). Identical scalar physical properties (m.p., b.p., density) in achiral environment, but rotate plane-polarised light in opposite directions and behave differently in chiral environments (chiral solvents, biological receptors). Pharmacologically relevant: thalidomide R-isomer is a sedative; S-isomer is teratogenic. Differentiate from diastereomers (non-mirror-image stereoisomers).

✔ Correct — B: Meso compound = stereoisomer with multiple stereocentres + an internal plane of symmetry → optically inactive (rotations cancel internally). Although individual stereocentres are present, the whole molecule is superimposable on its mirror image, hence ACHIRAL despite stereocentres. Classic example: meso-tartaric acid (2R,3S) — has internal mirror plane between C2 and C3. Distinct from enantiomers and racemic mixtures.

✔ Correct — D: CIP rules: (1) Higher atomic number = higher priority of the directly bonded atom (I > Br > Cl > O > N > C > H); (2) If tie, work outward atom-by-atom; (3) Treat double / triple bonds as duplicate atoms (C=O treated as C bonded to two O's, and O bonded to two C's); (4) Higher mass-number isotope wins ties at same atomic number. Then orient with lowest priority (usually H) AWAY → if 1 → 2 → 3 is clockwise = R, anticlockwise = S.

✔ Correct — A: Polarimeter measures optical rotation α — the angle through which plane-polarised monochromatic light is rotated by an optically active substance. Specific rotation [α]_D = α / (l × c), where l = path length (dm), c = concentration (g/mL); D refers to sodium D-line (589 nm). Reported in degrees with temperature and solvent (e.g., [α]²⁰_D = +52.7° (c 5, H₂O)). Used to characterise enantiopurity, monitor reactions, identify natural products.

✔ Correct — C: E/Z system uses CIP priorities at each sp² C of a C=C: identify higher-priority substituent on each carbon. Z (zusammen, German "together") = higher-priority groups on the SAME side; E (entgegen, "opposite") = higher-priority groups on OPPOSITE sides. Replaces older cis/trans for unambiguous tri- / tetrasubstituted alkenes. Z = polar geometry usually; E often more thermodynamically stable for substituted alkenes due to reduced steric strain.

✔ Correct — B: Newman projection of n-butane along C2-C3 bond — energy minimum is the ANTI-staggered conformation (methyl groups 180° apart): minimum steric repulsion + favourable hyperconjugation → 0 kJ/mol reference. Order: anti (0) < gauche (+ 3.8 kJ/mol, methyls 60° apart, slight steric strain) < eclipsed methyl-H (+ 16) < fully eclipsed methyl-methyl (+ 25). Free rotation at RT but population favours anti by Boltzmann distribution.

✔ Correct — A: Cyclohexane conformations (most → least stable): chair (0 kJ/mol — all bonds staggered, 109.5° angles) → twist-boat (+ 23) → boat (+ 29 — flagpole H-H repulsion + eclipsing) → half-chair (+ 45 — transition state). Chair flips between two interconverting forms (~ 10⁵ s⁻¹ at RT). Each carbon has one axial and one equatorial position; bulky substituents prefer equatorial (less steric 1,3-diaxial strain — A-value).

✔ Correct — C: Racemic mixture (or racemate, ± mixture) = 1:1 mixture of two enantiomers. Total optical rotation = 0 (rotations cancel). Synthetic achiral reactions usually give racemates. Resolution methods: chiral chromatography (chiral stationary phase), crystallisation of diastereomeric salts (with chiral resolving agent like brucine, quinine, tartaric acid), kinetic resolution (enzymatic — lipases), asymmetric synthesis (chiral catalysts). Pasteur's manual sorting of sodium ammonium tartrate crystals (1848) was the first resolution.

✔ Correct — D: Atropisomerism = stereoisomerism arising from restricted rotation around a single bond (rotational barrier ≥ 80 kJ/mol → distinct, isolable rotamers at room T). Common in biaryls with bulky ortho substituents (BINOL, BINAP), ansamacrolides, telmisartan-like drugs, vancomycin. The stereoisomers are termed atropisomers — labelled M (minus, anticlockwise) / P (plus, clockwise) or aS / aR. Important in chiral catalysts (BINAP-Ru, asymmetric hydrogenation) and FDA-approved drugs.

✔ Correct — B: D/L convention (Fischer): in a Fischer projection drawn vertically with the most-oxidised group (e.g., -CHO of glucose) at top, look at the LOWEST chiral carbon (in glucose, C5). If -OH is on the RIGHT → D-sugar; on LEFT → L-sugar. Most natural sugars (glucose, fructose, galactose) are D; most natural amino acids are L. D/L is independent of (+/−) optical rotation and from R/S — three separate naming systems. Glucose is D-(+)-glucose; (R) at C5.

✔ Correct — A: Tartaric acid has 2 stereocentres → max 2² = 4 expected. But internal symmetry (2R,3S = 2S,3R, mirror through C2-C3) gives ONE meso form (achiral). So only THREE distinct stereoisomers: (2R,3R) = (+)-tartaric (natural, dextro); (2S,3S) = (−)-tartaric (levo); meso (achiral). The (R,R) + (S,S) racemic mixture (DL-tartaric) is also called paratartaric acid (Pasteur's classical study).

✔ Correct — C: Two ways a chiral molecule (with stereocentres) can be optically inactive: (1) Meso compound — internal mirror plane cancels rotation within ONE molecule (achiral despite stereocentres); (2) Racemic mixture — equal amounts of (+) and (−) enantiomers cancel macroscopically. To distinguish: a meso compound is ONE pure substance, racemate is a MIXTURE. Resolution can separate racemate enantiomers but not meso (meso stays inactive). Common confusion in teaching.

✔ Correct — D: Geometric isomerism requires: (1) restricted rotation around the bond (typical for C=C double bonds, cyclic systems, or atropisomeric biaryls); (2) two DIFFERENT groups on each end of the bond — otherwise rotation gives identical molecules. cis = same-side / Z; trans = opposite-side / E. Without these conditions, no geometric isomerism (e.g., 1,1-dichloroethene has no isomer). Cyclopropane / cyclohexane substitution can also show cis-trans (same plane vs opposite plane).

✔ Correct — A: In a cyclohexane chair, each carbon has one axial (up/down) and one equatorial (out from ring) bond. Bulky substituents in axial position cause 1,3-diaxial steric clashes with the two H's on the same face → strained. Equatorial position points outward, no clash → preferred. A-value (free-energy preference) quantifies: methyl 1.7 kJ/mol, isopropyl 9, t-butyl 21 (almost always equatorial — practically locks the chair). Glucose β-anomer has all -OH equatorial → most stable.

✔ Correct — C: Biological receptors and enzymes are themselves chiral (built from L-amino acids and D-sugars) → discriminate between enantiomers. Levodopa (L-DOPA) is taken up by the same transporter that handles L-tyrosine and L-phenylalanine; D-DOPA is not. Active drug after decarboxylation = dopamine (achiral). Famous example: thalidomide (R-sedative; S-teratogenic — but they interconvert in vivo!). Single-enantiomer drugs like (S)-omeprazole (esomeprazole) and (S)-citalopram (escitalopram) — twice the potency at half the dose vs racemate.

✔ Correct — B: Classical resolution: mix the racemic acid (or base) with a chiral resolving agent (commonly brucine, strychnine, quinine, cinchonidine, (R)- or (S)-1-phenylethylamine, (+)- or (−)-tartaric acid, mandelic acid) → forms two diastereomeric salts → these have DIFFERENT solubilities → separate by selective crystallisation → release pure enantiomer by acid / base hydrolysis. Modern alternatives: chiral chromatography (Pirkle, cyclodextrin, polysaccharide CSPs), kinetic / dynamic kinetic resolution (lipase enzymes), asymmetric synthesis directly.

✔ Correct — A: Tertiary amines (R₁R₂R₃N:) with three different R groups are chiral on paper — but the N-pyramidal lone pair inverts (umbrella flip) through a planar transition state with a low barrier (~ 25 kJ/mol → ~ 10⁹ s⁻¹ at 25 °C) → both enantiomers interconvert too rapidly to isolate at room T. Quaternary ammonium salts (R₁R₂R₃R₄N⁺) lack lone pair → cannot invert → ARE configurationally stable and resolvable. Bridgehead amines (Trögers base) and aziridines (small ring constrains inversion) also resolvable.

✔ Correct — C: Optical purity = ([α]_observed / [α]_pure-enantiomer) × 100 %. Equivalent to enantiomeric excess (ee) = |[R] − [S]| / ([R] + [S]) × 100 %. Pure single enantiomer gives ee = 100 %; racemate ee = 0 %. Modern methods to determine ee: chiral HPLC (most accurate, separates enantiomers and integrates peaks), chiral GC, NMR with chiral shift reagents (Eu(hfc)₃, Pirkle's reagent), capillary electrophoresis with chiral selectors. Asymmetric reaction quality often reported as %ee (90 % ee = 95:5 ratio).

✔ Correct — B: BINOL (1,1'-bi-2-naphthol) and BINAP have bulky 2,2'-substituents that physically prevent the two naphthyl planes from coming coplanar → racemisation barrier > 100 kJ/mol → atropisomers stable for years at RT. Each is chiral (M / P or aR / aS). Used as ligands / catalysts in asymmetric synthesis — BINAP-Ru for Noyori asymmetric hydrogenation (Nobel Prize 2001). Also drugs: telmisartan, vancomycin contain atropisomeric centres.

✔ Correct — C: In pyrrole / furan / thiophene, the heteroatom (N, O, S) provides 2 electrons from its lone pair to the ring's aromatic π system → 4n+2 = 6 π e⁻ (n=1) → aromatic. The other lone pair (on O, S — but not on pyrrole's N which only has one) stays in an sp² orbital in the ring plane. Consequence: pyrrole is much LESS basic than pyridine because protonation would destroy aromaticity. Reactivity order toward EAS: pyrrole > furan > thiophene > benzene (heteroatom donates electrons).

✔ Correct — A: EAS on pyrrole occurs preferentially at C-2 (α-position) because the σ-complex (Wheland intermediate) at C-2 has THREE resonance structures stabilising the cation; attack at C-3 (β) gives only TWO resonance structures → less stable. Hence α >> β. Pyrrole is so reactive toward EAS that strong acids destroy it (oligomerisation); use mild conditions (e.g., acetic anhydride for acetylation, NaNO₂ / acetic acid for nitrosation). Furan and thiophene also α-selective.

✔ Correct — C: Imidazole pKa for protonation = 6.95 (basic ring N) — so at pH 7.4, mostly NEUTRAL (~ 75 % free base, ~ 25 % protonated). pKa for deprotonation of N-H = 14.5 → essentially no anionic form at physiological pH. Histidine residue in proteins (imidazole side chain) is the only amino acid whose pKa is near physiological pH → makes it ideal for general acid-base catalysis (carbonic anhydrase, serine proteases). Imidazole-based drugs: clotrimazole, ketoconazole, omeprazole, dacarbazine, metronidazole.

✔ Correct — B: Furan acts as a DIENE in Diels-Alder cycloaddition with dienophiles (maleic anhydride, dimethyl acetylenedicarboxylate, etc.) — gives an oxa-bicyclic adduct → aromaticity is LOST in the product (becomes a non-aromatic dihydrofuran-type bicycle). Pyrrole and thiophene are less reactive in Diels-Alder (more aromatic — break aromaticity less easily). Furan's lower aromatic stabilisation energy (~ 16 kcal/mol vs benzene's 36) explains its diene behaviour. Useful synthon in synthesis of natural-product-like skeletons.

✔ Correct — A: Aromatic stabilisation energy: thiophene (~ 29 kcal/mol) > pyrrole (~ 21) > furan (~ 16) > benzene reference (36). Counter-intuitive — thiophene is the closest to benzene because S 3p orbitals overlap nearly the same size as ring C 2p (better overlap than O or N second-period). Reactivity in EAS reverses this — most aromatic = least reactive: thiophene < pyrrole < furan (furan most reactive but least stable). Drug examples: thiophene in tiagabine, raloxifene; furan in furosemide; pyrrole in atorvastatin.

✔ Correct — B: Acid-catalysed epoxide opening — protonation of O makes ring more electrophilic; the C-O bond at the MORE-substituted carbon stretches first (carbocation-like TS, more stable cation centred on more substituted C); nucleophile attacks at that carbon → "Markovnikov-like" regiochemistry. Under BASIC / strong nucleophile conditions, attack occurs at the LESS-hindered (less substituted) carbon by SN2-like mechanism → "anti-Markovnikov". This dichotomy is exploited in synthesis (e.g., conversion of alkenes to anti diols via epoxide).

✔ Correct — C: β-Lactam = 4-membered cyclic amide. Strained ring (~ 25 kcal/mol ring strain) → carbonyl is highly electrophilic → acetylates the active-site Ser-OH of bacterial transpeptidase (PBP), blocking peptidoglycan cross-linking → bactericidal. Drugs: penicillins (with thiazolidine fused), cephalosporins (with dihydrothiazine), carbapenems, monobactams. β-Lactamases hydrolyse this ring → resistance. β-Lactamase inhibitors (clavulanate, sulbactam) protect the antibiotic.

✔ Correct — A: Aziridine (saturated 3-membered N-ring) — bond angles ~ 60° (vs ideal sp³ 109.5°) → ~ 27 kcal/mol ring strain. Reacts readily as a strong electrophile / alkylating agent — opens with nucleophiles (amines, thiols, halides). N-acylaziridines especially reactive (carbonyl-activated). Used as alkylating agent in anticancer drugs (mitomycin C, thiotepa) — DNA cross-linking. Aziridines also as building blocks for amino-containing molecules in synthesis.

✔ Correct — D: Pyrrole's N-H is mildly acidic (pKa ≈ 17 — between alcohol 16 and ammonia 35) because the conjugate base (pyrrolide anion) is aromatic and resonance-stabilised. Deprotonation needs strong base (NaH, NaNH₂, BuLi). Once formed, pyrrolide is nucleophilic at N (with hard electrophiles — N-alkylation) or at C (with soft electrophiles — C-acylation). Pyrrole itself is NON-basic (pKaH = -3.8) because protonation breaks aromaticity. Compare with pyridine (pKaH = 5.2, normal basicity).

✔ Correct — A: Thiamine (vitamin B1) contains a thiazolium (positively charged thiazole) ring linked to an aminopyrimidine. The thiazolium C-2 H is acidic (pKa ~ 18); deprotonated form acts as carbanion-equivalent → carries 2-carbon "active aldehyde" units in pyruvate dehydrogenase, transketolase, α-KG dehydrogenase, branched-chain α-keto dehydrogenase. Other thiazole drugs: ritonavir (HIV PI), meloxicam (NSAID), abafungin (antifungal), penicillin-G (fused with β-lactam). Thiazolium ylide also basis of NHC (N-heterocyclic carbene) catalysis.

✔ Correct — B: Paal-Knorr (1885): 1,4-dicarbonyl compound + acid catalyst (H₂SO₄ or P₂O₅) → cyclisation + dehydration → furan; with NH₃ / RNH₂ → pyrrole; with P₂S₅ (sulfur source) → thiophene. Same starting material → all three 5-membered heterocycles by choosing N-, O- or S-source. Useful "one-pot" method for pharmaceutical scaffold construction. Other classic 5-membered syntheses: Knorr pyrrole (β-aminoketones); Hantzsch pyrrole (β-ketoester + amine); Knorr furan; Hinsberg thiophene.

✔ Correct — A: Imidazole (1,3-diazole): 5-ring with two non-adjacent N's. Found in histidine, histamine, purines (adenine / guanine), nucleobases. Drug examples: cimetidine, ranitidine (H2-antagonists), ketoconazole, clotrimazole (antifungals), metronidazole (antibacterial / antiprotozoal), losartan (ARB). Pyrazole (1,2-diazole) — N's adjacent — found in celecoxib, sildenafil, fipronil. Thiazole has S+N (1,3); oxazole has O+N (1,3). Memorise: histamine = imidazole.

✔ Correct — C: Tetrazole (CN₄H) — pKa ~ 4.9, similar to carboxylic acid (RCOOH pKa 4-5) and similar charge / H-bond pattern at physiological pH (anion). Used as -COOH bioisostere — preserves binding, improves metabolic stability + lipophilicity (often). Examples: angiotensin-receptor blockers losartan, valsartan, irbesartan, candesartan have tetrazole replacing the -COOH of natural angiotensin-II. Other COOH bioisosteres: hydroxamic acid, sulfonamide, acyl-sulfonamide, hydroxyl-isoxazole.

✔ Correct — A: Fischer indole (Hermann Fischer, 1883) — phenylhydrazine + ketone (or aldehyde) + Brønsted/Lewis acid (HCl, H₂SO₄, ZnCl₂, BF₃) → arylhydrazone → tautomerises to ene-hydrazine → [3,3] sigmatropic rearrangement → cyclisation → loses NH₃ → indole. Most general indole synthesis. Drug-relevant: tryptamine, serotonin, indomethacin, sumatriptan, ondansetron. Bischler indole is alternative (α-haloketone + arylamine). Larock annulation (modern Pd-catalysed o-iodoaniline + alkyne).

✔ Correct — C: Omeprazole (Prilosec®) — substituted benzimidazole sulfoxide linked to substituted pyridine via -CH₂-S(O)-CH₂-. Pro-drug: in gastric parietal-cell acid environment (pH 1-2), it rearranges to a sulfenamide that covalently binds Cys-813 of H⁺/K⁺-ATPase → irreversible inhibition. Esomeprazole = pure (S)-enantiomer. Other PPIs: lansoprazole, pantoprazole, rabeprazole, dexlansoprazole — same benzimidazole + pyridine scaffold. First-line treatment for GERD, peptic ulcer, H. pylori eradication (with antibiotics).

✔ Correct — D: Like furan and pyrrole, thiophene undergoes EAS at the 2-position (α) preferentially — σ-complex at C-2 has more resonance contributors than at C-3. Selectivity is high (~ 6:1 α:β). Reactivity vs benzene: thiophene reacts ~ 10⁵× faster but less than pyrrole / furan. Common reactions: bromination, nitration (HNO₃ in Ac₂O), Vilsmeier formylation, Friedel-Crafts acylation. Thiophene is found in drugs: tiagabine, raloxifene, ticlopidine, clopidogrel, duloxetine.

✔ Correct — B: Pyrazole synthesis: hydrazine (H₂N-NH₂) + 1,3-diketone or β-ketoester → cyclo-condensation → pyrazole (or substituted pyrazole) with loss of 2 H₂O. Two N's of hydrazine become the 1,2-diaza of the ring. Drug examples with pyrazole core: celecoxib (COX-2 selective), sildenafil (PDE-5 — Viagra), rimonabant, anastrozole. Substituted hydrazines (PhNHNH₂ + 1,3-dicarbonyl) give N-aryl pyrazoles. Distinguishes from imidazole synthesis (which uses 1,2-diketone + aldehyde + ammonia).

✔ Correct — A: Oxazole motif appears in marine and bacterial alkaloid natural products: phorboxazole, telomestatin, virginiamycin (antibiotic), bengamide, tantazole. Often built biosynthetically from cyclisation / oxidation of serine / threonine residues in modified peptides (NRPS pathways). Synthetic drugs: oxaprozin (NSAID), aleglitazar (PPAR agonist). Isoxazole (1,2-O,N) is a common drug motif: leflunomide, valdecoxib, sulfamethoxazole, oxazepam. 4,5-dihydrooxazoles (oxazolines) are popular chiral ligands.

✔ Correct — D: Hückel's rule: aromatic systems need 4n+2 π electrons (n = 0, 1, 2 ...). 5-membered aromatic heterocycles (pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, isoxazole, isothiazole) all have 6 π electrons (n = 1) — heteroatom contributes lone pair (2 e⁻) + two C=C double bonds (4 e⁻) = 6. Cyclopentadienyl anion (C₅H₅⁻) is also 6-π aromatic 5-ring (carbocyclic). Tetrazole and triazoles likewise 6 π. Compare: cyclopentadiene (neutral) has only 4 π → not aromatic.

✔ Correct — A: Metronidazole (Flagyl®) — 5-nitroimidazole pro-drug. In anaerobic bacteria / protozoa, the -NO₂ is reduced (by ferredoxin / pyruvate-ferredoxin oxidoreductase) to a reactive nitro-radical anion that damages DNA → bactericidal. Selective for anaerobes (no electron carrier in aerobes to activate the drug). Uses: H. pylori (in triple therapy), C. difficile colitis, Trichomonas vaginalis, Giardia, Entamoeba histolytica, anaerobic infections (Bacteroides, Clostridium). Other 5-nitroimidazoles: tinidazole, ornidazole, secnidazole.

✔ Correct — C: Pyridine pKaH ≈ 5.2 in water (i.e., pyridinium ion C₅H₅NH⁺ has pKa ≈ 5.2). The N-lone pair sits in an sp² orbital in the plane of the ring (NOT part of the aromatic π-system), so it is available for protonation without disrupting aromaticity. However, sp² N is more electronegative than sp³ N → less basic than aliphatic amines (R₃N pKaH ~ 10-11). Compare: pyrrole pKaH ≈ -3.8 (lone pair IS in π-system; protonation destroys aromaticity → not basic). Substituents shift basicity: 4-DMAP pKaH ≈ 9.6 (much more basic — used as acyl-transfer catalyst); 2,6-lutidine pKaH ≈ 6.7.

✔ Correct — B: Pyridine is π-deficient (electronegative N withdraws density), so EAS is sluggish and requires harsh conditions (HNO₃ + H₂SO₄ at ~ 300 °C, or oleum-SO₃). When EAS does occur, attack is at C-3 (β-position). Reason: σ-complex from C-3 attack does NOT place positive charge on N (which would be highly destabilising for an electron-poor atom); attack at C-2 or C-4 puts (+) on N → forbidden. Pyridine N also coordinates with Lewis-acid catalysts → further deactivation. Pyridine N-oxide (PyN→O) reverses this: EAS on N-oxide goes at C-4 readily because the N⁺-O⁻ donates into ring.

✔ Correct — A: Chichibabin amination: pyridine + NaNH₂ in toluene / xylene / liquid NH₃ → 2-aminopyridine + H₂↑ (or NaH). Mechanism: amide nucleophile adds at C-2 (most electrophilic ring carbon — α to N stabilises the σ-adduct as a stable amide-like anion); rearomatisation by loss of H⁻ (which deprotonates a second NH₂⁻ → H₂ gas). Goes at 2-position because the σ-complex puts (-) on N (good — electronegative N stabilises). 2-aminopyridine is starting material for sulfa-drugs (sulfapyridine), antihistamines (pheniramine class), proton-pump inhibitors (omeprazole intermediate).

✔ Correct — D: Pyridine + peroxyacid (mCPBA / H₂O₂-AcOH) → pyridine N-oxide (Py-N⁺=O⁻). The N-O⁻ group is a strong π-donor (lone pair on O delocalises into ring) → activates ring towards EAS, with selectivity at C-4 (para to N⁺-O⁻). Nitration of pyridine N-oxide gives 4-nitropyridine N-oxide cleanly under mild conditions (compare bare pyridine: needs 300 °C). After EAS the N-oxide can be reduced back to pyridine using PCl₃ / PPh₃ / Fe-AcOH / H₂-Pd. Useful synthetic strategy: N-oxide → 4-functionalisation → deoxygenate.

✔ Correct — B: Isoniazid (INH) = isonicotinic acid hydrazide = pyridine-4-carbohydrazide. First-line anti-tubercular: a pro-drug activated by mycobacterial KatG (catalase-peroxidase) to an acyl radical that targets InhA (enoyl-ACP reductase) → blocks mycolic acid synthesis. Other pyridine-containing drugs: nicotinamide (vitamin B₃), pyridoxine (B₆), nicotinic acid (niacin), nicotine (tobacco alkaloid), pioglitazone, amlodipine (DHP-pyridine, BP), nifedipine, omeprazole (has pyridine + benzimidazole), loratadine (pyridyl-piperidine).

✔ Correct — C: Pyrimidine = 1,3-diazine — two N atoms at positions 1 and 3 of the 6-ring (meta-relationship). It is π-deficient (two electronegative N's withdraw from the ring → very poor EAS substrate; SNAr at C-2/C-4/C-6 instead). Biological importance: pyrimidine bases cytosine, thymine, uracil (DNA / RNA). Drug examples: 5-fluorouracil (anti-cancer, thymidylate synthase inhibitor), zidovudine (AZT — HIV NRTI), trimethoprim (DHFR inhibitor antibiotic), idoxuridine, sulfadiazine. Compare diazine isomers: pyridazine = 1,2-diazine; pyrazine = 1,4-diazine.

✔ Correct — A: Purine = pyrimidine fused with imidazole (4 N total: N-1, N-3 of pyrimidine + N-7, N-9 of imidazole). 9H-purine is the parent. Biological purines: adenine (6-aminopurine), guanine (2-amino-6-oxopurine), hypoxanthine (6-oxopurine), xanthine (2,6-dioxopurine), uric acid (2,6,8-trioxopurine — endpoint of purine catabolism, raised in gout). Methylated xanthines: caffeine (1,3,7-tri-Me xanthine), theophylline (1,3-di-Me — bronchodilator), theobromine (3,7-di-Me — cocoa). Purine drugs: 6-mercaptopurine, allopurinol (xanthine-oxidase inhibitor for gout), acyclovir, azathioprine.

✔ Correct — D: Allopurinol = 1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one = isomer of hypoxanthine (purin-6-one) where N-7 of imidazole is swapped to a pyrazole-type position. Mechanism: allopurinol is itself a substrate for xanthine oxidase (XO), being oxidised to oxipurinol (alloxanthine) which then potently inhibits XO → blocks hypoxanthine → xanthine → uric acid pathway → lowers serum urate. First-line urate-lowering therapy in chronic gout. Side effect: severe cutaneous reactions in HLA-B*5801 carriers (genetic test in some Asian populations). Modern alternative: febuxostat (non-purine XO inhibitor).

✔ Correct — B: 5-FU is a pyrimidine antimetabolite. Intracellular activation: 5-FU → FdUMP (fluorodeoxyuridine monophosphate) → covalent ternary complex with thymidylate synthase (TS) + 5,10-methylene-tetrahydrofolate. The fluorine at C-5 of uracil prevents the normal methylation step and traps TS as a stable enzyme adduct → blocks dUMP → dTMP conversion → "thymineless death" (cell cannot make DNA without thymidine). Also incorporated as FUTP into RNA (causing RNA dysfunction). Used in colorectal, breast, head/neck cancers. DPD-deficient patients (DPYD gene polymorphism) develop severe toxicity — pre-treatment screening recommended.

✔ Correct — A: Caffeine = 1,3,7-trimethylxanthine. Three methyl groups on the xanthine (2,6-dioxopurine) scaffold at N-1, N-3, N-7. Pharmacology: non-selective adenosine receptor antagonist (A₁, A₂A) → CNS stimulation, vasoconstriction; also inhibits phosphodiesterase (raises cAMP) at supratherapeutic doses. Related methylxanthines: theophylline (1,3-dimethylxanthine — bronchodilator in asthma, narrow therapeutic index, monitor levels); theobromine (3,7-dimethylxanthine — found in cocoa, mild diuretic). All three are caffeine relatives sharing the xanthine skeleton.

✔ Correct — C: Quinoline = benzo[b]pyridine — a benzene ring fused with pyridine such that the N is at position 1 of the bicyclic system. Isoquinoline = benzo[c]pyridine — N at position 2 (different fusion pattern). Both are weakly basic (quinoline pKaH ≈ 4.9, isoquinoline pKaH ≈ 5.4 — slightly more basic than pyridine due to extended π). Quinoline is famous for the alkaloid quinine (cinchona bark, antimalarial), chloroquine, hydroxychloroquine, primaquine, mefloquine — all antimalarials with quinoline core. Also quinolone antibiotics (ciprofloxacin, levofloxacin) — actually 4-quinolone (oxo at C-4).

✔ Correct — A: Skraup synthesis (1880): aniline + glycerol + concentrated H₂SO₄ + nitrobenzene (mild oxidant) → quinoline. Glycerol dehydrates in situ to acrolein (CH₂=CH-CHO); aniline does conjugate addition (N attacks β-C of acrolein, Michael), then the aldehyde cyclises onto the ortho-position of the aromatic ring (electrophilic), and finally nitrobenzene oxidises the dihydroquinoline to quinoline (the nitrobenzene also acts as solvent and prevents tar formation). Reaction is exothermic — usually moderated with FeSO₄ or As₂O₅. Substituted anilines give substituted quinolines following Skraup regiochemistry.

✔ Correct — D: Bischler-Napieralski reaction (1893): β-arylethylamide (ArCH₂CH₂NHCOR) + dehydrating agent (POCl₃ / P₂O₅ / ZnCl₂) → 3,4-dihydroisoquinoline. Mechanism: amide → nitrilium ion → intramolecular EAS onto aromatic ring → cyclisation. Subsequent oxidation (Pd-C / DDQ / S) gives full isoquinoline. Used in alkaloid synthesis: papaverine, coralydine, tetrahydroisoquinolines (THIQ scaffold = dopaminergic alkaloids — apomorphine, phenethylamines). Related: Pictet-Spengler reaction (β-arylethylamine + aldehyde + acid → THIQ directly, milder, biomimetic).

✔ Correct — B: Chloroquine concentrates in Plasmodium parasite's acidic food vacuole (via ion-trapping — quinoline N is protonated at low pH). It binds free heme (ferriprotoporphyrin IX, released when parasite digests host haemoglobin) and prevents its polymerisation into inert hemozoin (haem crystals). Unpolymerised free haem is toxic to the parasite (lipid peroxidation, membrane damage) → parasite death. Resistance: PfCRT mutations on the food-vacuole membrane efflux chloroquine. Other 4-aminoquinolines (amodiaquine, hydroxychloroquine) and 8-aminoquinolines (primaquine — gametocidal, hepatic) share related but distinct mechanisms.

✔ Correct — A: Papaverine = 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline — non-narcotic opium alkaloid (Papaver somniferum). Mechanism: phosphodiesterase inhibitor → raises cyclic AMP / cGMP → vasodilatation, smooth-muscle relaxation. Used clinically for cerebral and peripheral vasospasm, intra-cavernosal injection in erectile dysfunction (older agent), refractory tachycardia. Other isoquinoline alkaloids: morphine and codeine (phenanthrene-isoquinoline core), tubocurarine (bisbenzyl-THIQ → muscle relaxant), berberine (protoberberine THIQ — antimicrobial), emetine (ipecac, anti-amoebic).

✔ Correct — C: Indole = benzo[b]pyrrole — benzene fused to pyrrole sharing C-2 and C-3 of pyrrole as the fused edge. Numbering: N-1, C-2, C-3 (most reactive in EAS, β-position relative to N), then C-3a, C-4, C-5, C-6, C-7, C-7a. EAS of indole goes preferentially at C-3 (most stable σ-complex preserves the benzene ring aromaticity). Indole is weakly basic — N protonation at C-3 (not N-1) under strong acid. Tryptophan, tryptamine, serotonin (5-HT, 5-hydroxytryptamine), melatonin, indomethacin, sumatriptan, vincristine all share the indole core.

✔ Correct — B: Fischer indole synthesis (1883): arylhydrazine (PhNHNH₂) + ketone or aldehyde with α-CH → arylhydrazone → tautomerise to ene-hydrazine → [3,3] sigmatropic rearrangement (the Fischer step) → bis-imine → cyclisation + loss of NH₃ → 2,3-disubstituted indole. Acid catalysts: ZnCl₂, HCl, H₂SO₄, polyphosphoric acid. Excellent for making 2,3-disubstituted indoles (e.g., antimigraine triptans). Limitation: regiochemistry with unsymmetrical ketones — usually the more substituted enamine forms preferentially (2-substituted-3-alkyl indoles).

✔ Correct — D: Serotonin = 5-hydroxytryptamine (5-HT) = 5-hydroxyindole-3-ethylamine — indole scaffold with -OH at C-5 and -CH₂CH₂NH₂ at C-3. Synthesised from tryptophan via tryptophan hydroxylase (rate-limiting, BH₄ cofactor) → 5-HTP → AADC → serotonin. Major sites: enterochromaffin cells in gut (90 % of body 5-HT), CNS (raphe nuclei), platelets. Functions: mood, appetite, sleep, GI motility, vasoconstriction, platelet aggregation. Receptors: 5-HT₁ to 5-HT₇ subfamilies (mostly GPCRs; 5-HT₃ is a ligand-gated ion channel — antiemetic target — ondansetron). Drug examples: SSRIs (fluoxetine), triptans (sumatriptan — 5-HT₁B/D agonist), ondansetron, ergotamine.

✔ Correct — A: Pictet-Spengler reaction (1911): β-arylethylamine (e.g., dopamine, phenethylamine) + aldehyde + acid → iminium ion → intramolecular Mannich-type EAS at the ortho-C of the activated aromatic ring → 1,2,3,4-tetrahydroisoquinoline (THIQ). When the arylamine is a tryptamine (indole + ethylamine), product is a tetrahydro-β-carboline (Pictet-Spengler in indole alkaloid biosynthesis — yohimbine, reserpine, vinca-alkaloids, harmaline). Biomimetic — happens in plants and (controversially) in mammalian brain (formation of trace alkaloid TIQs from dopamine + acetaldehyde — implicated in alcohol-related neurodegeneration).

✔ Correct — B: Acridine = dibenzo[b,e]pyridine — a central pyridine ring linearly fused with two benzene rings (analogue of anthracene with N at C-10 of central ring). Planar tricyclic, π-rich, fluorescent (used as DNA-staining dye — acridine orange). Drug examples: aminacrine / acriflavine (topical antiseptic), proflavine (intercalator), amsacrine (m-AMSA, antileukemic — topo II poison + DNA intercalator), quinacrine (antimalarial — also studied for prion disease, anti-inflammatory). Acridine bisects DNA between adjacent base pairs (intercalation) → unwinds and lengthens duplex → blocks transcription / replication.

✔ Correct — A: Claisen condensation: two ester molecules + strong base (NaOEt for ethyl esters, NaH, LDA) → β-ketoester. Mechanism: (1) base deprotonates α-C of ester (pKa ~ 25, not so acidic, so a STOICHIOMETRIC strong base is required — must match the ester's alkoxide group to avoid trans-esterification); (2) the enolate attacks the carbonyl of a second ester; (3) loss of -OR; (4) the product β-ketoester (pKa ~ 11) is deprotonated by base, irreversibly driving equilibrium forward. Acidic workup at the end protonates the enolate to give neutral β-ketoester. Classic example: 2 ethyl acetate → ethyl acetoacetate. Crossed Claisen: 2 different esters work only if one ester has no α-H (e.g., aromatic ester, formate, oxalate, carbonate).

✔ Correct — C: Aldol "condensation" = aldol addition + dehydration. Step 1 (Aldol addition): NaOH (or other base) deprotonates α-C of carbonyl (pKa ~ 20) → enolate → attacks second carbonyl → β-hydroxy carbonyl ("aldol"). Step 2 (Condensation / dehydration): under heat or further base, the β-hydroxy carbonyl loses H₂O via E1cb mechanism → α,β-unsaturated carbonyl (enone or enal). Driving force: extended conjugation. Example: 2 acetaldehyde → 3-hydroxybutanal (aldol) → but-2-enal / crotonaldehyde (condensed). Crossed aldol works best when one carbonyl has no α-H. Industrial: butanal → 2-ethyl-hexenal → 2-ethylhexanol (plasticiser DOP precursor).

✔ Correct — D: Cannizzaro reaction (1853): non-enolisable aldehyde (no α-H) + concentrated NaOH → 50 % carboxylic acid (oxidised) + 50 % alcohol (reduced) — disproportionation / redox between two molecules of the same aldehyde. Mechanism: hydroxide adds to one aldehyde → tetrahedral alkoxide; this transfers a hydride (H⁻) to a second aldehyde → first molecule becomes carboxylate, second becomes alkoxide / alcohol. Examples: HCHO → HCOO⁻ + CH₃OH; PhCHO → PhCOO⁻ + PhCH₂OH; (CH₃)₃CCHO → pivalate + neopentyl alcohol. Crossed Cannizzaro: paraformaldehyde + non-enolisable aldehyde — formaldehyde always reduces (preferentially); used for primary alcohol synthesis.

✔ Correct — B: Reformatsky reaction (1887): α-bromo-ester (BrCH₂COOR) + Zn dust in benzene / THF → zinc enolate (BrZn-CH₂COOR) → adds to aldehyde / ketone carbonyl → after acidic workup gives β-hydroxy ester. Why Zn (not Mg)? Zn enolate is "soft" and selective (does NOT attack the ester carbonyl of its own molecule, unlike a Grignard which would self-destruct on the ester). This makes Reformatsky a controlled way to add an "ester-enolate equivalent" to aldehydes. Modern alternative: lithium ester enolates (with LDA at -78 °C) — same disconnection. β-Hydroxy esters can dehydrate to α,β-unsat-esters (Mukaiyama / Knoevenagel-type).

✔ Correct — A: Diels-Alder (1928, Nobel 1950): diene + dienophile → cyclohexene via concerted [4+2] cycloaddition. Diene must be in s-cis conformation so the two terminal carbons (C-1 and C-4) can reach the two ends of the dienophile (C=C). Acyclic dienes equilibrate s-cis ⇌ s-trans (s-trans usually more stable but unreactive); cyclic dienes locked in s-cis (cyclopentadiene, furan) react fast. Dienophile typically electron-poor (EWG: CHO, COR, COOR, CN, NO₂) — "normal-demand DA". Stereochemistry: cis on dienophile stays cis in product (suprafacial); endo product favoured (kinetic — secondary orbital interactions). Famous example: cyclopentadiene + maleic anhydride → endo-norbornene-anhydride.

✔ Correct — C: Wittig reaction (1954, Nobel 1979): phosphorus ylide (Ph₃P=CR₂, made from Ph₃P + R-CH₂-X then base) + aldehyde / ketone → alkene + Ph₃P=O (driving force is the strong P=O bond, ~ 130 kcal/mol). Mechanism: ylide attacks carbonyl → 4-ring oxaphosphetane → retro-[2+2] gives alkene + phosphine oxide. Stereoselectivity: stabilised ylides (R = COOR, COPh, CN) give E-alkene; non-stabilised ylides give Z-alkene; semi-stabilised ylides give mixtures. Used in vitamin-A synthesis (BASF), prostaglandin synthesis. Variants: Horner-Wadsworth-Emmons (HWE — phosphonate ester, gives E-alkene), Schlosser modification (Z to E).

✔ Correct — B: Friedel-Crafts acylation (1877): ArH + RCOCl + anhydrous AlCl₃ → Ar-COR + HCl. AlCl₃ activates acid chloride by abstracting Cl⁻ → acylium cation [RCO]⁺ (resonance-stabilised: R-C≡O⁺). Acylium attacks aromatic ring (EAS) → ketone product. Note: F-C acylation does NOT suffer from over-reaction (the product ketone is deactivated by C=O — only mono-acylation, unlike F-C alkylation which can give multiple substitutions and rearrangement). AlCl₃ binds the ketone product → must use ≥ 1 equiv (stoichiometric, not truly catalytic). Inactivation: strongly deactivated rings (NO₂, NR₃⁺) don't react. Other Lewis acids work too (FeCl₃, ZnCl₂) but AlCl₃ is the classic.

✔ Correct — A: Beckmann rearrangement (1886): ketoxime (R₁R₂C=N-OH) + strong acid (H₂SO₄ / PCl₅ / SOCl₂ / TsCl) → amide. Mechanism: -OH protonates → leaves as H₂O; concertedly, the alkyl group anti-periplanar to the leaving group migrates from C to N → nitrilium → water trap → amide. Migration is stereospecific: the group anti to the OH migrates. Industrially huge: cyclohexanone oxime → caprolactam (precursor of nylon-6) by H₂SO₄. With unsymmetrical ketoximes, the syn/anti geometry of the oxime determines product structure (used to differentiate isomeric oximes — the Beckmann test).

✔ Correct — D: Mannich reaction: enolisable C-H acid (ketone, ester, β-ketoester, phenol, terminal alkyne) + CH₂O + secondary amine (R₂NH) → β-amino-carbonyl ("Mannich base"). Mechanism: amine + HCHO → iminium ion (R₂N⁺=CH₂) → attacked by enol / enolate of the C-H acid → β-amino-ketone. Examples: acetophenone + HCHO + Me₂NH → Ph-CO-CH₂-CH₂-NMe₂ (Mannich base; on β-elimination gives α,β-unsat-ketone — methyl vinyl ketone equivalent). Industrial relevance: tropinone synthesis (Robinson, 1917) is a double Mannich. Drug examples: ranitidine, fluoxetine, atropine — all involve Mannich-style C-N bond formation.

✔ Correct — C: Hofmann rearrangement (bromamide degradation, 1881): primary amide (RCONH₂) + Br₂ + NaOH (or NaOBr) → primary amine (RNH₂) + Na₂CO₃. Mechanism: N-bromoamide → deprotonation → N-bromo-anion (nitrene-like) → migration of R from C to N (concerted with -Br loss) → isocyanate (R-N=C=O) → hydrolysis → carbamic acid → -CO₂ → primary amine. Stereochemistry: migration is intramolecular with retention at the migrating carbon. Result: amine has ONE LESS carbon than amide. Useful for making primary amines free of contaminating R₂NH and R₃N (unlike alkylation of NH₃ which over-alkylates). Related: Curtius (acyl azide → isocyanate → amine) and Lossen (hydroxamate → amine) follow same logic.

✔ Correct — A: Schmidt reaction (1924): carbonyl + HN₃ + strong acid (H₂SO₄ / TfOH) → product depends on substrate: ketones → amides (with insertion of N — same outcome as Beckmann); carboxylic acids → primary amines + CO₂ + N₂ (one carbon shorter — same outcome as Hofmann / Curtius); aldehydes → nitriles (or formamides). Mechanism (ketone case): protonated C=O + HN₃ → tetrahedral hydrazoic adduct → loss of H₂O → diazoiminium → N₂ extrudes with concerted alkyl migration → nitrilium → water trap → amide. Schmidt is intramolecular: anti-periplanar migration of group anti to N₂.

✔ Correct — B: Wolff-Kishner reduction (1911): C=O + H₂N-NH₂ + KOH (in ethylene glycol or DMSO) at high T (~ 200 °C) → C-H₂ (methylene) + N₂↑. Mechanism: ketone + hydrazine → hydrazone (R₂C=N-NH₂) → base deprotonates → diazoanion → loss of N₂ with concerted protonation of carbon → CH₂ product. Stoichiometry: C=O → CH₂ — net deoxygenation, with retention of the original carbon framework. Useful for: reducing aryl ketones to alkylarenes (R-Ar). Strongly basic conditions — limits substrate (no acid-sensitive groups, no easily hydrolysable esters). Counterpart in acidic medium: Clemmensen reduction (Zn-Hg + HCl) — same C=O → CH₂ outcome but acid stable.

✔ Correct — D: Clemmensen reduction (1913): C=O + Zn-Hg amalgam + concentrated HCl + heat → CH₂. Same overall outcome as Wolff-Kishner (deoxygenation, C=O → CH₂), but acidic conditions tolerate base-sensitive functional groups (esters, base-labile substrates), and conversely cannot be used on acid-sensitive groups (alcohols, ethers may dehydrate; acetals hydrolyse). Useful for reducing the keto product of Friedel-Crafts acylation back to the alkylated arene (since direct F-C alkylation gives rearrangement / poly-alkylation, you do F-C acylation first, then Clemmensen). Mechanism: poorly understood — likely involves carbenoid / radical intermediates on the Zn surface.

✔ Correct — C: Hell-Volhard-Zelinsky (HVZ, 1881): RCH₂COOH + Br₂ + cat PBr₃ (or red P) → R-CHBr-COOH (α-bromo acid) + HBr. Mechanism: PBr₃ converts -COOH → -COBr (acid bromide); enol of acid bromide is more readily formed than enol of acid (Br vs OH on C=O); the enol α-brominates (electrophilic Br⁺ from Br₂); after exchange of -Br for -OH (with another acid), final product is α-bromo carboxylic acid. α-Bromo acids are versatile intermediates: SN2 with NH₃ gives α-amino acid (one of the classic amino-acid syntheses); E2 gives α,β-unsat-acid; with KOH gives α-hydroxy acid; precursor to many drug syntheses. Limitation: only α-H of -COOH is brominated (not α-H of ketone — that's plain α-halogenation).

✔ Correct — B: Reimer-Tiemann (1876): phenol + CHCl₃ + NaOH → ortho-hydroxybenzaldehyde (salicylaldehyde) as major + para-isomer minor. Mechanism: NaOH deprotonates CHCl₃ → CCl₃⁻ → loses Cl⁻ to give dichlorocarbene (:CCl₂); phenolate (PhO⁻) attacks :CCl₂ at the ortho-position via cyclohexadienone intermediate; hydrolysis of -CCl₂H by NaOH gives -CHO. Ortho-selectivity from intramolecular delivery of carbene by phenolate. Salicylaldehyde is precursor of salicylic acid → aspirin (acetylsalicylic acid). Variants: Reimer-Tiemann with CCl₄ → salicylic acid directly (carboxylation instead of formylation).

✔ Correct — A: Perkin reaction (1868): aromatic aldehyde (ArCHO, e.g., benzaldehyde) + acid anhydride [(RCH₂CO)₂O, e.g., acetic anhydride] + base catalyst (sodium acetate, K₂CO₃, or amine) at elevated temperature → α,β-unsaturated aromatic acid (cinnamic acid type). Mechanism: anhydride enolises (α-deprotonation by AcO⁻) → enolate attacks ArCHO → β-hydroxy adduct → cyclic ester intermediate → β-elimination + hydrolysis → cinnamic acid (E-PhCH=CHCOOH). Used historically for synthesis of cinnamic acids, coumarins, and the dye industry. Sodium acetate / K₂CO₃ are mild bases compatible with the anhydride reagent.

✔ Correct — C: Knoevenagel condensation (1894): aldehyde / ketone + 1,3-dicarbonyl compound (active methylene with two flanking EWG, pKa ~ 9-13) + amine catalyst (piperidine, pyridine, ammonium acetate — Doebner modification) → α,β-unsaturated carbonyl product. Substrates with 1,3-dicarbonyl: malonate (CH₂(COOR)₂), malonic acid, β-ketoester (CH₃COCH₂COOR), 1,3-diketone, cyanoacetate (NCCH₂COOR), nitromethane (Henry reaction is the nitro variant). Mechanism: amine + ArCHO → iminium → attacked by stabilised C-nucleophile of active methylene → β-amino product → E1cb dehydration → enone. Doebner version: with malonic acid + pyridine → in situ decarboxylation gives an α,β-unsat-acid (cinnamic acid).

✔ Correct — D: Benzoin condensation: 2 PhCHO + cat NaCN (or KCN, or thiamine / NHC for green version) → α-hydroxy ketone (PhCH(OH)-CO-Ph, "benzoin"). Mechanism: CN⁻ adds to one PhCHO → cyanohydrin alkoxide; the α-CN stabilises a carbanion (cyanide is "umpolung" reagent — flips carbonyl from electrophilic to nucleophilic); this acyl anion equivalent attacks a second PhCHO → after CN⁻ loss, gives benzoin. Without CN⁻, no benzoin (PhCHO has no α-H so cannot do aldol). Modern green version: thiamine pyrophosphate (vitamin B₁) — bio-mimetic catalyst (same role in pyruvate decarboxylase enzyme); N-heterocyclic carbenes (NHCs) are best modern catalysts. Benzoin → benzil (oxidation, HNO₃) → benzilic acid rearrangement (KOH).

✔ Correct — B: Sandmeyer reaction (1884): ArN₂⁺ + CuX (X = Cl, Br, CN) → ArX + N₂↑ + Cu⁺. Mechanism: radical — Cu(I) reduces diazonium → Ar• + N₂ + CuX → Cu(II) transfers X• to Ar• → ArX. Variants by halide: CuCl/HCl → ArCl; CuBr/HBr → ArBr; CuCN/KCN → ArCN; CuSO₄/H₂SO₄ + Δ → ArOH (hydrolysis); HBF₄ → ArF (Schiemann); KI (no Cu needed) → ArI; H₃PO₂ → ArH (deamination). The diazonium intermediate (made from ArNH₂ + NaNO₂ + HCl at 0–5 °C) is the workhorse for installing X, OH, CN, NO₂ etc. on a benzene ring without using harsh EAS conditions. Indispensable in dye chemistry and pharmaceutical synthesis.

✔ Correct — A: Suzuki-Miyaura coupling (1979, Nobel 2010): ArX + Ar'B(OH)₂ + cat Pd(PPh₃)₄ (or Pd(OAc)₂ / Pd₂(dba)₃ + ligand) + base (Na₂CO₃ / K₃PO₄) → Ar-Ar' + Pd(0) regenerated. Mechanism: (1) Pd(0) oxidative addition into Ar-X → Ar-Pd(II)-X; (2) base displaces halide and forms Ar-Pd-OH (or with boronate, Ar-Pd-OAr'); (3) transmetallation transfers Ar' from boron to Pd → Ar-Pd-Ar'; (4) reductive elimination → Ar-Ar' + Pd(0). Hugely used in pharmaceutical synthesis (e.g., losartan, valsartan, crizotinib) — clean, mild, water-tolerant, low boronic-acid toxicity. Other Pd cross-couplings: Heck (ArX + alkene), Negishi (ArX + ArZnX), Stille (ArX + ArSnR₃), Sonogashira (ArX + alkyne), Buchwald-Hartwig (ArX + amine).

✔ Correct — B: Glucose = aldohexose (CHO at C-1, six carbons total, C₆H₁₂O₆); fructose = ketohexose (C=O at C-2, six carbons, same molecular formula). Both are isomers of formula C₆H₁₂O₆ but differ in carbonyl position. Other key sugars: ribose = aldopentose (RNA backbone, C₅H₁₀O₅); deoxyribose = aldopentose with -OH replaced by H at C-2 (DNA backbone); galactose = aldohexose epimer of glucose (at C-4); mannose = aldohexose epimer of glucose (at C-2). Aldoses are reducing sugars (Fehling, Tollens, Benedict positive); ketoses with α-hydroxyketone group can also reduce these reagents (fructose isomerises in base to glucose / mannose via enolate).

✔ Correct — C: In Haworth (D-sugars, ring O at upper right), C-1 anomeric -OH is shown DOWN for α-anomer and UP for β-anomer. In the chair (⁴C₁ for D-glucopyranose), C-1 -OH down = axial in α; up = equatorial in β. Therefore β-D-glucopyranose (all -OH equatorial) is more stable than α — this is one reason glucose dominates in nature. Equilibrium in water at 25 °C: ~36 % α-D-glucose, ~64 % β-D-glucose, < 0.1 % open chain (mutarotation, [α] = +52.7°, equilibrium between [α] = +112° (α) and +18.7° (β)). Anomeric effect: in α-form, axial OR (or any electronegative group) at C-1 is stabilised by hyperconjugation (O-lone-pair → C-1-O σ*) — explains why α can persist despite steric penalty.

✔ Correct — A: Mutarotation: spontaneous change in optical rotation of a freshly dissolved reducing sugar in water until equilibrium. Mechanism: anomeric carbon (C-1 of pyranose, formed when C-1 -CHO closes onto C-5 -OH) is a hemiacetal — it can open (to free aldehyde, achiral at C-1) and re-close to either α or β anomer. Pure α-D-glucose ([α] = +112°) → equilibrium ([α] = +52.7°); pure β ([α] = +18.7°) → same equilibrium. Catalysed by acid or base (concerted general acid / base in proton shuffling). All reducing sugars (free anomeric C) show mutarotation; non-reducing disaccharides (sucrose — both anomeric C tied up) do NOT mutarotate. Optical rotation tracks the changing α : β ratio over time.

✔ Correct — D: Glycosidic bond formation: anomeric C-1 -OH of one sugar + any -OH (commonly C-4 -OH for backbone, C-2 / C-3 / C-6 for branches) of another sugar → loss of H₂O → C-O-C glycosidic linkage. It is an acetal / ketal (anomeric C-1 has one OR external + one OR ring → no longer hemiacetal → no longer reducing). Examples: maltose (Glc-α-1,4-Glc, reducing); cellobiose (Glc-β-1,4-Glc, reducing); sucrose (Glc-α-1,β-2-Fru, non-reducing — both anomeric C engaged); lactose (Gal-β-1,4-Glc, reducing); trehalose (Glc-α-1,α-1-Glc, non-reducing). Hydrolysis of glycosides: acid (H₃O⁺) or enzymatic (glycosidase, e.g., maltase, lactase, sucrase, β-glucuronidase).

✔ Correct — A: Sucrose = α-D-glucopyranosyl-(1→2)-β-D-fructofuranoside. Bond is between C-1 anomeric of α-glucose and C-2 anomeric of β-fructose. Since BOTH anomeric carbons are tied up in the glycosidic linkage, sucrose has no free reducing end → it is a NON-reducing sugar (negative Fehling's, Benedict's, Tollens'). This is the only common disaccharide that is non-reducing (along with trehalose). Hydrolysis of sucrose by sucrase (or dilute acid) gives equimolar glucose + fructose ("invert sugar" — name reflects the change in optical rotation from + 66.5° (sucrose) to negative as fructose [α] = -92° dominates the post-hydrolysis sign).

✔ Correct — C: Fehling's reagent: equimolar Fehling's A (CuSO₄ aq) + Fehling's B (sodium potassium tartrate + NaOH). On heating with reducing sugar, the deep blue Cu(II)-tartrate complex is reduced to a brick-red precipitate of Cu₂O (cuprous oxide). The aldehyde group of the sugar is concurrently oxidised to a carboxylic acid (aldonic acid). Positive: aldoses (glucose, galactose, mannose), reducing disaccharides (maltose, lactose), some α-hydroxyketoses (fructose — via enolisation). Negative: sucrose, glycosides, polysaccharides (no free anomeric C). Variants: Benedict's reagent (cu-citrate, more stable in acidic urine — used for glycosuria diagnosis); Tollens (Ag-NH₃ → Ag mirror); Barfoed (acidic Cu acetate — distinguishes monosaccharides from disaccharides).

✔ Correct — A: Osazone formation: monosaccharide (with -CHO at C-1, -OH at C-2) + 3 mol PhNHNH₂ → osazone (yellow crystals) + NH₃ + PhNH₂ + H₂O. Mechanism: 1st PhNHNH₂ forms phenylhydrazone at C-1; 2nd is oxidant — converts C-2 -CH(OH)- to C-2 -C=O (oxidation); 3rd PhNHNH₂ forms hydrazone at the new C-2 -C=O. Final: bis-phenylhydrazone at C-1 + C-2. Stops at C-2 (no further oxidation): chelation / H-bond with C-1 hydrazone protects C-3. Significance: glucose, mannose, fructose ALL give the SAME osazone (because they differ only at C-1 and / or C-2 — the very atoms that are derivatised, "erasing" the difference). Used historically by Emil Fischer to deduce sugar configurations (Fischer's proof).

✔ Correct — B: Cellulose = β-D-glucose units linked β-(1→4) → linear straight chain (β-orientation puts each successive glucose flipped 180° → forms extended ribbon-like polymer). Adjacent chains H-bond strongly → microfibrils → very high tensile strength + insolubility → structural component of plant cell walls (and most abundant organic polymer on Earth). Humans CANNOT digest cellulose — we lack β-glucosidase (cellulase) enzyme. Ruminants (cows) and termites use symbiotic gut microbes (e.g., Bacteroides, Trichonympha) to hydrolyse cellulose. Compare: starch (amylose) is α-(1→4) Glc → coiled helix → digestible by α-amylase (pancreatic + salivary) → glucose for energy.

✔ Correct — D: Starch ≈ 20-25 % amylose + 75-80 % amylopectin (varies by plant source). Amylose: linear chain of α-D-glucose linked α-(1→4); coils into a helix (~ 6 Glc per turn). Amylopectin: same α-(1→4) backbone PLUS α-(1→6) branch points every ~ 24-30 residues — gives a tree-like branched structure. Iodine test: amylose binds I₂ in helix → deep BLUE-BLACK colour; amylopectin gives RED-VIOLET (shorter helices). Glycogen (animal storage in liver / muscle) has the same structure as amylopectin but more highly branched (every ~ 8-12 residues) — gives RED with iodine. Hydrolysis: α-amylase (endo, breaks α-1,4) + α-1,6-glucosidase (debranch) → glucose for ATP via glycolysis.

✔ Correct — A: Heparin is a heavily sulfated linear polysaccharide of repeating disaccharide units of α-L-iduronic acid (or D-glucuronic acid) and α-D-glucosamine — a member of the glycosaminoglycan (GAG) family. The high density of -SO₃⁻ and -COO⁻ groups gives it the highest negative charge density of any biological macromolecule. Mechanism (anticoagulant): a specific pentasaccharide segment binds antithrombin III (AT-III) → conformational change → AT-III inactivates thrombin (IIa) and factor Xa ~1000-fold faster (catalytic enhancement). LMW heparins (enoxaparin, dalteparin) selectively boost anti-Xa activity. Other GAGs: hyaluronic acid (joints), chondroitin sulfate (cartilage), keratan sulfate, dermatan sulfate. (PCI BP401T Unit V — Carbohydrates, GPAT 2023 S1 polysaccharide entry from master index.)

✔ Correct — C: Ruff degradation (1898): aldose (e.g., D-glucose) is first oxidised by Br₂ + H₂O to aldonic acid (gluconic acid); the calcium salt (Ca-gluconate) is treated with H₂O₂ + Fe(III) acetate (Fenton-like) → C-1 -COOH is decarboxylated AND C-2 is oxidised to a new -CHO → product = aldose with one less carbon (D-glucose → D-arabinose; D-arabinose → D-erythrose). Wohl degradation does the same (one C shorter aldose) by a different route: aldose → oxime (NH₂OH) → acetylated oxime → ammonia loss to nitrile → loss of HCN gives shorter aldose. Together, Wohl and Ruff reduce sugars by ONE carbon. The OPPOSITE process (lengthen by one carbon) is Kiliani-Fischer (HCN + hydrolysis + reduction).

✔ Correct — B: Kiliani-Fischer synthesis (1885 / 1890): aldose (Cn) + HCN → cyanohydrin (Cn+1) → hydrolyse to aldonic acid → reduce (Na/Hg, originally; modern: H₂/Pd-BaSO₄ Rosenmund-style on lactone) → aldose (Cn+1). Net: chain LENGTHENED by 1 carbon at the C-1 end. Stereochemistry: HCN addition creates a new stereocenter at C-2 → gives a pair of C-2 epimers (e.g., D-arabinose → D-glucose + D-mannose, the C-2 epimers, in roughly equal amounts). Used historically to relate sugars in homologous series. Together with Ruff/Wohl (chain shortening), Kiliani-Fischer maps the entire D-aldose family from glyceraldehyde upward (Fischer's classic 1891 proof of glucose stereochemistry).

✔ Correct — A: Epimers = diastereomers differing at only one stereocenter (other than the anomeric C). D-glucose vs D-mannose: differ at C-2 only (glucose: 2R; mannose: 2S — or, in Fischer projection, OH right vs left at C-2). D-glucose vs D-galactose: differ at C-4 (C-4 epimers — galactose -OH points opposite). Anomers (e.g., α-D-glucose vs β-D-glucose) are a special case of epimers — differ at the anomeric C-1 only. Importance: enzymes are stereo-specific — galactosemia patients lack galactose-1-P uridyltransferase → cannot metabolise galactose → toxicity. Mannose: hexokinase phosphorylates mannose to M6P → enters glycolysis or mannose-rich glycoprotein synthesis.

✔ Correct — D: Most mammals biosynthesise vitamin C from D-glucose: glucose → glucuronate (UDP-glucuronic acid pathway) → L-gulonate → L-gulonolactone → L-ascorbic acid. Final step requires gulonolactone oxidase (GULO). Humans, primates, guinea pigs, fruit bats LACK functional GULO (pseudogene) → must obtain vitamin C from diet → deficiency causes scurvy (defective collagen hydroxylation — Pro/Lys hydroxylase needs ascorbate as cofactor). Structure: ascorbic acid is a γ-lactone of an aldonic acid + has a 2,3-enediol → highly acidic (pKa₁ ≈ 4.2) and powerful reductant (donates 2 e⁻ → dehydroascorbate, which is recycled by glutathione). Functions: collagen, neurotransmitter (NA) synthesis, antioxidant, iron absorption.

✔ Correct — B: Lactose (Gal-β-1,4-Glc) is cleaved by lactase (β-galactosidase, also called LCT in humans) — a brush-border enzyme of the small-intestinal enterocytes — into D-galactose + D-glucose. Lactase activity declines after weaning in most populations (lactase non-persistence, ~ 65 % of world adults) → lactose intolerance: undigested lactose is fermented by colonic flora → gas, bloating, osmotic diarrhoea. Lactase persistence (continued expression in adulthood) is a classic example of recent human evolution, common in northern Europeans, some African pastoralists. Other common deficiencies: galactosemia (galactose-1P uridyltransferase deficiency — separate problem); congenital sucrase-isomaltase deficiency.

✔ Correct — A: D / L convention (Fischer 1891) refers to the highest-numbered chiral centre — for hexose, that's C-5. In the Fischer projection of D-glucose, the C-5 -OH is on the RIGHT side (drawn with -CHO at top, -CH₂OH at bottom). CIP assignment of C-5 (priorities: O > C-6 (CH₂OH) > C-4 (chain) > H): visually, the ring-O > C-6 > C-4 → tracing the priorities with H pointing away (it does, in Fischer down-bottom convention with horizontal lines forward) → traces clockwise → R configuration. By contrast, L-glucose has -OH on the LEFT at C-5 → S configuration. The D / L system survives in carbohydrate (and amino acid) nomenclature because it is concise; CIP R / S is the universal modern descriptor.

✔ Correct — C: Reduction of D-glucose: -CHO at C-1 → -CH₂OH gives D-glucitol = D-sorbitol (a hexitol; six -OH polyol). Sorbitol is widely used as a low-calorie sweetener (~ 60 % as sweet as sucrose), humectant in toothpaste, IV diuretic / osmotic agent, excipient in chewable tablets and elixirs (sugar-free). Naturally found in apples, peaches, prunes (causes their laxative effect — sorbitol is poorly absorbed → osmotic load in colon → fermented). In diabetes, intracellular accumulation of sorbitol (via aldose reductase, enzyme overactive in hyperglycaemia) contributes to cataract formation, neuropathy, retinopathy — sorbitol cannot exit cells and draws water in. Reduction of D-mannose gives D-mannitol (a similar polyol used as IV osmotic diuretic).

✔ Correct — D: Three classes of glucose oxidation products: (1) ALDONIC acids — only -CHO at C-1 oxidised → -COOH; reagents: Br₂/H₂O, Fehling, Tollens, Benedict, glucose oxidase (enzymatic) → D-gluconic acid. (2) URONIC acids — only -CH₂OH at C-6 oxidised to -COOH (selective enzymatic / protected synthesis) → D-glucuronic acid (involved in phase II hepatic conjugation: bilirubin glucuronide, drug glucuronides — UGT enzymes). (3) ALDARIC (saccharic / glycaric) acids — BOTH C-1 -CHO AND C-6 -CH₂OH oxidised → -COOH at both ends; reagent: HNO₃ → D-glucaric acid. Glucaric acid is centrosymmetric on paper but D-glucaric is NOT meso (would need to be — it isn't due to differing internal stereochem).

✔ Correct — B: Furanose = 5-membered cyclic hemiacetal of a sugar (named after furan, the parent aromatic 5-O ring). Pyranose = 6-membered cyclic hemiacetal (named after pyran, the parent saturated 6-O ring). Most aldohexoses (glucose, galactose, mannose) preferentially form pyranose (6-ring) — more stable (less ring strain). Aldopentoses (ribose, deoxyribose) and ketohexoses (fructose) often form furanose. Examples: D-glucose ≈ 99 % glucopyranose at equilibrium; D-fructose ≈ 67 % β-D-fructopyranose + ~ 30 % β-D-fructofuranose at 25 °C, but in disaccharides like sucrose, fructose is locked as fructofuranose; in DNA / RNA, ribose / deoxyribose are always furanose.

✔ Correct — C: Glycogen has the SAME architecture as amylopectin: α-(1→4)-linked D-glucose backbone with α-(1→6) branch points — except glycogen is MORE highly branched (every ~ 8-12 residues vs every ~ 24-30 in amylopectin). Why? Branches expose many non-reducing ends (where glycogen phosphorylase / synthase act) → rapid glucose mobilisation and storage. Stored mainly in liver (~ 100 g, regulates blood glucose between meals) and skeletal muscle (~ 400 g, used locally for muscle contraction, no exit since muscle lacks glucose-6-phosphatase). Glycogen synthesis: glucose → G-6-P → G-1-P → UDP-glucose → added by glycogen synthase + branching enzyme. Breakdown: glycogen phosphorylase + debranching enzyme. Defects: glycogen storage diseases (von Gierke type I — G-6-Pase deficiency; Pompe type II — α-glucosidase / GAA; McArdle V — myophosphorylase).